SPYRE THERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886.0K | $2.3M | $18.7M | $0 | $0 | $3.9M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | $58.6M | $57.1M | $59.6M | $64.6M | $36.7M |
| SG&A Expense | $47.9M | $45.8M | $39.9M | $28.5M | $27.3M | $21.8M | $15.7M | $12.6M |
| Operating Income | $-209.6M | $-208.6M | $-242.3M | $-84.8M | $-65.6M | $-81.5M | $-80.3M | $-45.5M |
| Operating Margin | — | — | -27,348.0% | -3,640.2% | -350.3% | — | — | -1,169.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-155.2M | $-208.0M | $-338.8M | $-84.0M | $-65.7M | $-80.9M | $-78.3M | — |
| Income Tax Expense | $-15.0K | $51.0K | $-26.0K | $-136.0K | $141.0K | $0 | $0 | $0 |
| Net Income | $-155.2M | $-208.0M | $-338.8M | $-83.8M | $-65.8M | $-80.9M | $-78.3M | $-44.3M |
| Net Margin | — | — | -38,238.1% | -3,598.8% | -351.1% | — | — | -1,140.6% |
| EPS (Basic) | — | — | $13.76 | $-12.43 | $-12.51 | $-0.76 | $-1.23 | $-1.07 |
| EPS (Diluted) | — | — | $13.76 | $-12.43 | $-12.51 | $-0.76 | $-1.23 | $-1.07 |
| Shares Outstanding (Basic) | 78.2M | 60.3M | 6.9M | 6.7M | 5.3M | 106.7M | 58.2M | 48.3M |
| Shares Outstanding (Diluted) | 78.2M | 60.3M | 6.9M | 6.7M | 5.3M | 106.7M | 58.2M | 48.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |